Angeles Wealth Management LLC Purchases Shares of 1,682 Repligen Corporation $RGEN

Angeles Wealth Management LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,682 shares of the biotechnology company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Alliance Wealth Advisors LLC UT boosted its position in shares of Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 89 shares in the last quarter. State of Michigan Retirement System boosted its position in shares of Repligen by 0.8% during the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after purchasing an additional 100 shares in the last quarter. State of Wyoming boosted its position in shares of Repligen by 5.2% during the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 115 shares in the last quarter. Finally, Signaturefd LLC boosted its position in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus bought 1,800 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Down 1.3%

RGEN stock opened at $152.60 on Friday. The stock’s 50 day simple moving average is $128.81 and its 200 day simple moving average is $126.29. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a market cap of $8.59 billion, a P/E ratio of -610.38, a price-to-earnings-growth ratio of 2.82 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period last year, the company posted $0.40 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on RGEN shares. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Jefferies Financial Group cut their target price on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, September 12th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Stephens raised Repligen to an “overweight” rating and set a $160.00 price target on the stock in a research note on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $169.62.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.